Brief: Neurizon Therapeutics Says U.S. FDA Placed Co's Investigational New Drug Application Under Clinical Hold
17/01/2025 01:26
Jan 17 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX :
* U.S. FDA PLACED CO'S INVESTIGATIONAL NEW DRUG APPLICATION
FOR
NUZ-001 UNDER CLINICAL HOLD
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility